报名：首届全球心血管大会 | 最新议程 合作伙伴征集：2025全球手术机器人大会 近日， 美国胶囊内窥镜公司CapsoVision 向美国证券交易委员会（SEC）提交首次公开募股（IPO）申请， 计 划筹资最高3000万美元（约合2.2亿人民币） 。根据S-1文件，公司拟发行约250万股普通股，发行价格区间为 每股10至12美元，股票代码为"CAPS"，预计将登陆纳斯达克市场。 公司此次上市旨在强化其在非侵入性消化道诊断领域的布局。此次IPO预计将加快CapsoCam Plus的全球商业化 推进，并为下一代产品研发及全球供应链优化提供资金保障。 此次IPO募集资金将主要用于CapsoCam Plus产品的市场推广、下一代技术的研发、生产扩张及债务偿还，以增 强公司整体财务结构和市场竞争力。 # 产 品简介 CapsoVision的核心产品为 CapsoCam Plus ，是一款专用于小肠检查的可吞咽式胶囊内窥镜，提供非侵入性、 高图像质量的消化道检查手段。 产品自2016年获FDA 510(k)认证以来，已成为公司商业化主力， 并于2025年 获得用于2岁及以上儿童患者的适应症扩展， 进一步打开儿科诊断市场。 ...

Core Insights - The report titled "Ciming Beijing 2024 Annual Health Checkup Big Data Blue Book" was jointly released by Ciming Health Checkup, Zhongguancun Meian Health Industry Research Institute, and Beijing Evening News, incorporating a sample size of over 1.1 million people [1][2] - The report highlights a significant increase in the detection rates of health issues such as lung nodules and obesity, with obesity detection rising from 55.1% in 2023 to 56.4% in 2024, and lung nodule detection increasing from 52.6% to 59.3% [1][4] Health Data Analysis - The sample analyzed in the report included 1.1346 million individuals, with an average age of 43, and a gender distribution of 51.9% male and 48.1% female [2] - The report emphasizes the importance of health checkup data application in promoting health awareness and management, aligning with national health initiatives [2] Specific Health Findings - Lung nodule detection rates showed no significant gender difference, with males at 58.1% and females at 60.6%, and detection rates increased with age [4] - Obesity detection rates exhibited a notable gender disparity, with males at 69.4% compared to females at 42.7%, particularly high among males aged 45-49 at 76.9% [4] - The detection rate of thyroid nodules decreased slightly from 52.4% to 51.3%, possibly due to increased awareness and intervention measures [4][5] Gender-Specific Health Issues - The report indicates that male central obesity detection rates are higher at 52%, with the highest rates in the 55-59 age group at 60.9% [6] - Male fatty liver detection rates are concerning at 53.7%, particularly high in the 45-49 age group at 62.5% [8] - The detection rate of carotid artery plaques was 27.4%, with males at 32.3% and females at 22.4%, increasing with age [9] Innovative Health Management Products - Ciming Health Checkup introduced three innovative health management products focused on weight management, blood sugar management, and an upgraded magnetic capsule endoscopy system [12][13] - The weight management product includes various services aimed at providing effective weight control solutions through personalized interventions [12] - The upgraded magnetic capsule endoscopy system offers a non-invasive and efficient method for gastrointestinal examinations, enhancing patient experience [13] Future Directions - Ciming Health Checkup plans to continue developing innovative products in areas such as cancer screening, chronic disease management, and mental health, contributing to public health improvement [14]

学分会常委兼秘书长王占山致辞 5月7日下午，《慈铭北京·2024年度健康体检大数据蓝皮书》暨健康管理创新产品发布会在慈铭大厦召 开。 会上，慈铭体检与中关村美年健康产业研究院、北京晚报联合发布《慈铭北京·2024年度健康体检大数 据蓝皮书》（以下简称《蓝皮书》），通过持续追踪区域人群健康趋势，期望为公共卫生研究提供动态 观测窗口，为医疗机构优化疾病筛查路径提供参考基准，助力公众提升健康风险认知水平。现场还发布 了体重管理、血糖管理、"磁控胶囊胃镜系统"机器人PRO升级版三款健康管理创新产品。通过智能技术 赋能与定制化服务体系的深度融合，构建差异化解决方案，为公众提供更具针对性、高效性的健康管理 工具，助力提升全民健康素养。 中华医学会健康管理学分会常委兼秘书长王占山、北京健康管理协会会长高小俊、北京医学会健康管理 分会候任主委王鹏出席活动并致辞。 美年健康集团总裁、慈铭集团总裁徐涛致辞并发布《蓝皮书》，慈铭集团副总裁、营销中心总经理郭征 对三款健康管理创新产品做了详细讲解。 据徐涛介绍，《蓝皮书》研究数据来源于慈铭体检2024年度北京市19家体检中心的健康体检数据，纳入 分析的人群样本量为113.46万，聚焦 ...